LON:DPH - Dechra Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 2,992 +24.00 (+0.81 %)
(As of 07/20/2018 04:00 PM ET)
Previous CloseGBX 2,992
Today's RangeGBX 2,948 - GBX 2,996
52-Week RangeGBX 1,622 - GBX 2,720
Volume260,097 shs
Average Volume282,452 shs
Market Capitalization£2.73 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Dechra Pharmaceuticals logoDechra Pharmaceuticals plc develops, manufactures, sells, and markets veterinary pharmaceuticals and related products for veterinarians worldwide. The company operates through the European Pharmaceuticals, the North American Pharmaceuticals, and the Pharmaceuticals Research and Development segments. It offers various endocrinology, dermatology and care, anesthesia and analgesia, cardiovascular disease, ophthalmology, and equine medicine products; food producing animal antimicrobials; poultry vaccines; and pet diets. The company markets and distributes veterinary pharmaceuticals and equipment; provides financial services; and manufactures human and veterinary pharmaceutical products for third party customers. Dechra Pharmaceuticals plc markets its products through wholesaler and distributor networks. The company was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:DPH
CUSIPN/A
Phone+44-1606-814730

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.15%
Return on Equity9.08%
Return on Assets4.25%

Miscellaneous

EmployeesN/A
Outstanding Shares93,420,000
Market Cap£2,730.00

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals declared a dividend on Monday, February 26th. Shareholders of record on Thursday, March 8th will be paid a dividend of GBX 7.33 per share on Friday, April 6th. This represents a yield of 0.29%. The ex-dividend date of this dividend is Thursday, March 8th. The official announcement can be viewed at this link. View Dechra Pharmaceuticals' Dividend History.

What price target have analysts set for DPH?

3 analysts have issued 1 year target prices for Dechra Pharmaceuticals' stock. Their predictions range from GBX 2,400 to GBX 2,950. On average, they expect Dechra Pharmaceuticals' stock price to reach GBX 2,660.33 in the next year. This suggests that the stock has a possible downside of 11.1%. View Analyst Ratings for Dechra Pharmaceuticals.

What is the consensus analysts' recommendation for Dechra Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Dechra Pharmaceuticals' key competitors?

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the folowing people:
  • Mr. Ian D. Page, CEO, MD & Exec. Director (Age 57)
  • Mr. Richard John Cotton BA Hons, FCMA, CFO & Director (Age 57)
  • Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 55)
  • Ms. Andrea Dodds, Group Marketing Director
  • Ms. Katy Clough, Group HR Director

Has Dechra Pharmaceuticals been receiving favorable news coverage?

Press coverage about DPH stock has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Dechra Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also gave news coverage about the company an impact score of 45.86 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 2,992.

How big of a company is Dechra Pharmaceuticals?

Dechra Pharmaceuticals has a market capitalization of £2.73 billion.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.


MarketBeat Community Rating for Dechra Pharmaceuticals (LON DPH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals and other stocks. Vote "Outperform" if you believe DPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.